Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: Results from the confirm (coronary CT angiography evaluation for clinical outcomes: An international multicenter registry) registry

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 981-989

  Chow, Benjamin J W ^a   Small, Gary ^a   Yam, Yeung ^a   Chen, Li ^a   McPherson, Ruth ^a   Achenbach, Stephan ^b   Al Mallah, Mouaz ^c   Berman, Daniel S ^x   Budoff, Matthew J ^e   Cademartiri, Filippo ^f,g   Callister, Tracy Q ^h   Chang, Hyuk Jae ⁱ   Cheng, Victor Y ^d   Chinnaiyan, Kavitha ^j   Cury, Ricardo ^k   Delago, Augustin ^l,m   Dunning, Allison ^a   Feuchtner, Gundrun ^p   Hadamitzky, Martin ^q   Hausleiter, Jörg ^q   Karlsberg, Ronald P ^r   Kaufmann, Philipp A ^s   Kim, Yong Jin ^t   Leipsic, Jonathon ^u   Labounty, Troy ^d   Lin, Fay ⁿ   Maffei, Erica ^f,g   Raff, Gilbert L ^j   Shaw, Leslee J ^v   Villines, Todd C ^w   Min, James K ^o   more..

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f Cardiovascular Radiology Unit Division Giovanni XXIII Hospital   (Italy)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h Tennessee Heart and Vascular Institute   (United States)

ⁱ Yonsei University Health System   (South Korea)

^j WILLIAM BEAUMONT HOSPITAL   (United States)

^k BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

^l Capitol Cardiology Associates   (United States)

^m MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

ⁿ Medicine and Radiology   (United States)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^r Cardiovascular Medical Group   (United States)

^s UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^t Seoul National University Hospital   (South Korea)

^u UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^v EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w WALTER REED ARMY MEDICAL CENTER   (United States)

^x Walter Reed Medical Center ^*

more..

Author keywords

aspirin; coronary angiography; coronary atherosclerosis; mortality; prognosis; statin

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTITHROMBOCYTIC AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; AGED; ASIA; CANADA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; EUROPE; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROTECTION; RADIOGRAPHY; REGISTER; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ASIA; ASPIRIN; CANADA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 84931262246     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304351     Document Type: Article

References (33)

1. Chow BJ, Abraham A, Wells GA, Chen L, Ruddy TD, Yam Y, Govas N, Galbraith PD, Dennie C, Beanlands RS. Diagnostic accuracy and impact of computed tomographic coronary angiography on utilization of invasive coronary angiography. Circ Cardiovasc Imaging. 2009;2:16-23. doi: 10.1161/CIRCIMAGING.108.792572.
2. Chow BJ, Wells GA, Chen L, Yam Y, Galiwango P, Abraham A, Sheth T, Dennie C, Beanlands RS, Ruddy TD. Prognostic value of 64-slice cardiac computed tomography severity of coronary artery disease, coronary atherosclerosis, and left ventricular ejection fraction. J Am Coll Cardiol. 2010;55:1017-1028. doi: 10.1016/j.jacc.2009.10.039.
3. Chow BJ, Freeman MR, Bowen JM, et al. Ontario multidetector computed tomographic coronary angiography study: field evaluation of diagnostic accuracy. Arch Intern Med. 2011;171:1021-1029. doi: 10.1001/ archinternmed.2011.74.
4. Leber AW, Knez A, von Ziegler F, Becker A, Nikolaou K, Paul S, Wintersperger B, Reiser M, Becker CR, Steinbeck G, Boekstegers P. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: A comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardiol. 2005;46:147-154. doi: 10.1016/j.jacc.2005.03.071.
5. Kass M, Glover CA, Labinaz M, So DY, Chen L, Yam Y, Chow BJ. Lesion characteristics and coronary stent selection with computed tomographic coronary angiography: A pilot investigation comparing CTA, QCA and IVUS. J Invasive Cardiol. 2010;22:328-334.
6. van Velzen JE, Schuijf JD, de Graaf FR, Boersma E, Pundziute G, Spanó F, Boogers MJ, Schalij MJ, Kroft LJ, de Roos A, Jukema JW, van der Wall EE, Bax JJ. Diagnostic performance of non-invasive multidetector computed tomography coronary angiography to detect coronary artery disease using different endpoints: detection of significant stenosis vs. detection of atherosclerosis. Eur Heart J. 2011;32:637-645. doi: 10.1093/eurheartj/ ehq395.
7. Pohle K, Achenbach S, Macneill B, Ropers D, Ferencik M, Moselewski F, Hoffmann U, Brady TJ, Jang IK, Daniel WG. Characterization of non-calcified coronary atherosclerotic plaque by multi-detector row CT: comparison to IVUS. Atherosclerosis. 2007;190:174-180. doi: 10.1016/j. atherosclerosis.2006.01.013.
8. National Cholesterol Education Program Expert Pane on Detection... Final Report Washington, DC. National Institutes of Health; 2009.
9. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-579.
10. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;CD004816.
11. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: A meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024-1031. doi: 10.1001/archinternmed.2010.182.
12. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-1860.
13. Ostrom MP, Gopal A, Ahmadi N, Nasir K, Yang E, Kakadiaris I, Flores F, Mao SS, Budoff MJ. Mortality incidence and the severity of coronary atherosclerosis assessed by computed tomography angiography. J Am Coll Cardiol. 2008;52:1335-1343. doi: 10.1016/j.jacc.2008.07.027.
14. Jespersen L, Hvelplund A, Abildstrøm SZ, Pedersen F, Galatius S, Madsen JK, Jørgensen E, Kelbæk H, Prescott E. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734-744. doi: 10.1093/eurheartj/ehr331.
15. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol. 1974;33:87-94.
16. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
17. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307. doi: 10.1056/NEJM199511163332001.
19. Shepherd J, Blauw GJ, Murphy MB, et al.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623-1630.
20. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478-1485. doi: 10.2337/dc05-2415.
21. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816. doi: 10.1161/01.CIR.0000146378.65439.7A.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
23. Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS. Evidence-based use of statins for primary prevention of cardiovascular disease. Am J Med. 2012;125:440-446. doi: 10.1016/j.amjmed.2011.11.013.
24. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572-582. doi: 10.1016/j.jacc.2011.09.067.
25. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol. 2011;27:208-221. doi: 10.1016/j. cjca.2010.12.033.
26. Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff MJ. Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis. 2006;185:394-399. doi: 10.1016/j. atherosclerosis.2005.06.018.
27. Orakzai RH, Nasir K, Orakzai SH, Kalia N, Gopal A, Musunuru K, Blumenthal RS, Budoff MJ. Effect of patient visualization of coronary calcium by electron beam computed tomography on changes in beneficial lifestyle behaviors. Am J Cardiol. 2008;101:999-1002. doi: 10.1016/j. amjcard.2007.11.059.
28. Wong ND, Detrano RC, Diamond G, Rezayat C, Mahmoudi R, Chong EC, Tang W, Puentes G, Kang X, Abrahamson D. Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? Am J Cardiol. 1996;78:1220-1223.
29. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/ NEJMoa0807646.
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
32. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149-1158. doi: 10.1016/ S0140-6736(03)12948-0.
33. Blaha M, Budoff MJ, Shaw LJ, Khosa F, Rumberger JA, Berman D, Callister T, Raggi P, Blumenthal RS, Nasir K. Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging. 2009;2:692-700. doi: 10.1016/j.jcmg.2009.03.009.